Oct 2026· JCO Oncology Practice· Vol 22, pp. 749-749· 0 citations
TL;DR
Evaluation frameworks should extend beyond quantitative endpoints to capture how AI reshapes clinical relationships, redistributes professional authority, and influences team-based care delivery.
Abstract
749
Background:
Despite growing enthusiasm for healthcare artificial intelligence (AI), no studies have examined how AI reshapes clinical team dynamics and decision-making within a randomized controlled trial (RCT). This leaves a critical gap in understanding how human–AI interaction redistributes authority and influences team-based cancer care.
Methods:
This qualitative study was conducted in two waves (2024 and 2026) in an academic radiation oncology department following the SHIELD-RT RCT (NCT04277650), in which an electronic health record–based machine learning algorithm identified patients at high risk for acute care during radiotherapy and significantly reduced acute care utilization. We conducted 30 semi-structured interviews with 29 clinicians (10 radiation oncologists, 4 advanced practice providers, 5 nurses, and 10 radiation therapists), analyzed using abductive analysis combining grounded theory and thematic analysis.
Results:
SHIELD-RT filled "authority gaps"—mismatches between staff expertise and their structural ability to act on it. For nurses, it enhanced predictive capability, enabling proactive care within their existing clinical authority; for radiation therapists, it validated observational knowledge and lent legitimacy to escalate patient concerns. These mechanisms expanded frontline clinician contributions to decision-making while preserving physician oversight. Notably, these improvements were sustained after trial completion. Effects were contingent on the algorithm's scientific credibility, universal accessibility across roles, seamless workflow integration, and organizational leadership endorsement.
Conclusions:
Clinical AI designed with attention to professional roles and decision-making structures can expand frontline clinician contributions to cancer care without disrupting physician oversight. Evaluation frameworks should extend beyond quantitative endpoints to capture how AI reshapes clinical relationships, redistributes professional authority, and influences team-based care delivery.
How SHIELD-RT completed and activated frontline staff authority.
Dimension
Nurses
Radiation Therapists
Theoretical point
Component held
Affordances (formal standing to act and direct care)
Expertise (tacit predictive knowledge from daily contact)
Groups hold different single components, not uniformly low authority
Component lacking
Predictive expertise (practice was reactive)
Affordances (no standing to compel action)
Authority is partial in systematically different ways
Mechanism
Expertise augmentation
Affordance extension
One technology completes authority via opposite mechanisms
Result
Acts predictively through existing standing
Observations gain legitimacy and compel action
Expanded participation; physician jurisdiction intact (non-zero-sum)
400
Background:
Artificial intelligence (AI) is being integrated throughout the cancer care continuum, from administrative functions to diagnostic and monitoring processes, yet substantial concerns regarding implementation and quality remain. One important concern is that it will exacerbate inequities already p...
C. Ducille, K. Glynn, U. B. Basu Roy et al.· JCO Oncology Practice· 0 citations
428
Background:
Artificial intelligence (AI) is increasingly incorporated into healthcare, yet patient perspectives on AI in oncology remain underexplored. Cancer presents an important clinical context, characterized by high stakes, uncertainty, and longitudinal clinician-patient relationships. Understanding pa...
A. Lipitz-Snyderman, S. Chimonas, Jennifer Prey Dawson et al.· JCO Oncology Practice· 0 citations
685
Background:
Oncologists increasingly use clinical artificial intelligence (AI) tools in their decision-making. Understanding that use is central to ensuring AI only maintains or improves patient care quality. Over 1,450 AI-enabled medical devices are FDA-authorized, and most US health systems report AI depl...
The study concludes that successful implementation of AI-based CDSS requires not only technical accuracy but also transparency, adequate training, workflow integration, and clear accountability structures.
Hamza Hussein, I. Dahir, Linnea Carlsson et al.· 0 citations
712
Background:
Artificial intelligence (AI) is gaining attention in oncology care for its potential to improve operational efficiency, reduce administrative burden, and support clinical workflows. However, concerns about governance, safety, workforce readiness, and clinical integration may hinder adoption. To...
Teresa van Oort, Bianca Alvarez, C. Offit et al.· JCO Oncology Practice· 0 citations
Background Physicians’ confidence in clinical AI tools and perceptions of their effectiveness can influence the adoption of these tools in practice, which in turn, could affect the quality of patient care. However, the factors shaping these perceptions remain poorly understood. Methods We surveyed U.S. family medicine...
Bohye Kim, Katie Ryan, M. Kasun et al.· Research Square· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.